Any new drug or vaccine must undergo years of laboratory analysis in test tubes and animals before it ever reaches the public. But there always comes a point when people have to serve as guinea pigs. Last week officials at the National Institute of Allergy and Infectious Diseases in Bethesda, Md., announced that the first U.S.-approved human tests of a potential AIDS vaccine would begin this fall. The preparation, developed by MicroGeneSys of West Haven, Conn., consists of the outershell protein of the AIDS virus, which researchers hope will stimulate the body into producing an immune response against the intact invader....
To continue reading:
or
Log-In
